MANUFACTURING EXECUTION SYSTEM PROVIDERS IN HEALTHCARE MARKET

Every year, the healthcare industry generates a massive amount of data. In fact, the healthcare data currently constitutes around 30% share of the global data volume. Further, it is estimated that, by 2025, the data generated via the healthcare sector will rise at a compound annual growth rate of 36%.

It is important to consider that the constant management of such enormous volumes of data is a quite tedious process and challenging process. Specifically, management and handling of huge datasets in the healthcare industry often requires a large workforce of specialized personnel. According to the American Hospital Association, by 2026, there is likely to be a shortage of 3.2 million healthcare workers. The continuously growing data, coupled to the projected deficit of healthcare workers, would inadvertently generate pressure on healthcare manufacturers to adopt novel tools / technologies that can improve management efficiency and better utilize the available, expensive resources. Moreover, increasing complexity of healthcare manufacturing operations, along with growing stringency and frequent changes in regulatory requirements has created a dire need for adoption of automated solutions, such as manufacturing execution systems (MES). It is worth mentioning that, in the past few years, substantial acquisition activity has been reported in the manufacturing execution systems market, as players strive to become one-stop-shops, to cater to the diverse needs of the healthcare sector.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/manufacturin

In recent years, several healthcare stakeholders have actively undertaken initiatives to incorporate a manufacturing execution system into their production lines, with an aim to connect, monitor and control the complex manufacturing process. In addition, players are integrating advanced technologies, including internet of thing (IoT) and artificial intelligence (AI), in order to collect and analyze large volume of data from various sources, as well as to produce value in the form of insights, predictions and actions. According to industry experts, MES has the potential to reduce 10%-30% of the overall production cost depending on the type of industry. It has further been observed that companies are increasingly adopting cloud-based manufacturing execution system, to overcome the challenges associated with growing complexity of processes and global expansion of businesses. Specifically, cloud-based MES integrates real-time information of different production floors and promotes collaboration. Driven by the ongoing innovation in the industry, as well as the rise in demand for automated solutions, the manufacturing execution system providers market for the healthcare sector is likely to witness positive growth over the coming years.

For additional details, please visit
https://www.rootsanalysis.com/....reports/manufacturin or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com

The companion diagnostics development services market, is anticipated to grow at a CAGR of over 10%

Given the various challenges associated with co-development of companion diagnostics and drug / therapy, drug developers prefer to rely on third-party service providers that offer customized services and advanced technologies.

Roots Analysis has announced the addition of “Companion Diagnostics Development Services Market (2nd Edition), 2022-2035” report to its list of offerings.

The growing pipeline of patient-centric targeted therapies has led to a surge in demand for companion diagnostics; these tests are known to improve the success rates of late-stage trials by almost three-fold. The development and approval of these FDA classified high-risk devices requires multidisciplinary expertise and an established network of R&D and production facilities that can be accessed through service providers.

Key Market Insights

Over 150 companies claim to offer companion diagnostics development services, globally
Nearly 60% of the aforementioned players are based in North America, followed by the players located in Europe (30%). Further, this segment of the industry is dominated by the presence of mid-sized players (51-200 employees), which represent 40% of the total service providers.

Nearly 15% players claim to act as one-stop shops, offering services, ranging from biomarker discovery and development to manufacturing and commercialization
Most of the service providers (127) provide assay development services, followed by companies (124) offering services for biomarker discovery / identification. Further, NGS is the most popular technique, employed by over 100 service providers.

Over 90 companies are actively involved in the development of companion diagnostics
Nearly 91% of the total tests can detect mutations in a single biomarker. Amongst these, ErbB gene family (HER-2 and EGFR genes), PD-L1 genes, RAS gene family (KRAS and NRAS genes), BRCA gene family (BRCA1 and BRCA2) and BRAF emerged as the key genes which are assessed by majority of the companion diagnostics.

Partnership activity in this domain has increased at a CAGR of ~25%, between 2017 and 2021
Mergers and acquisitions, product development agreements and product development and commercialization agreements account for more than 60% of the total number of deals inked during the given time period. It is worth highlighting that nearly 25% of the total number of deals were signed in 2021. Further, the maximum number (177) of partnerships have been inked for companion diagnostics being developed for the treatment of oncological disorders.


North America is expected to capture ~60% share in the companion diagnostics development services market by 2035
Owing to the high costs associated with the clinical validation of companion diagnostics, a significant proportion (~46%) of service revenues is generated from this step, in 2035. In terms of analytical technique used, service contracts involving NGS are anticipated to contribute to more than 35% of the total service revenues generated in 2035. Further, close to 90% of the total service revenues, in 2035, are generated from companion diagnostics development projects for cancer indications.


To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/....reports/297/request-

One of the key objectives of the report was to estimate the existing companion diagnostics market size and the potential future growth opportunities for companion diagnostics development service providers. Based on multiple parameters, such as the service cost of various steps involved in companion diagnostics development and manufacturing, and partnerships inked in the last few years for outsourcing of such operations, we have developed informed estimates on the evolution of the market for the time period 2022- 2035.


For additional details, please visit
https://www.rootsanalysis.com/....reports/view_documen or email sales@rootsanalysis.com


You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2022-2035

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com

The biopharmaceutical contract manufacturing market is projected to grow at a CAGR of 10% during 2022-2035, claims Roots Analysis

With the advent of novel technologies and rising preference for such therapeutic interventions, biologics have made a significant impact in the pharmaceutical domain, delivering a ground-breaking treatment regimen for a myriad of disease indications.

London
Roots Analysis has announced the addition of the “Biopharmaceutical Contract Manufacturing Market, 2022–2035” report to its list of offerings.

In pursuit of both time and cost savings, as well as to access higher scales of production, outsourcing has emerged as a lucrative option for biologic drug developers. Driven by several blockbuster products, a burgeoning pipeline of biologic drugs, the demand for reliable contract service providers, which have the required expertise and advanced manufacturing capabilities, is expected to grow at a commendable pace in the coming years. Currently over 275 companies claim to be biopharma CDMO / biopharma CMO, in compliance with the regulatory standards. It is also worth highlighting that biopharmaceutical contract manufacturers are actively trying to consolidate their presence in this field by entering into strategic alliances in order to meet the indubitably rising demand for biologics. In 2021, a sum of over USD 70 billion was invested in the cell and gene therapy domain. However, biologics manufacturing is fraught with various challenges.

To request a sample copy / brochure of this report, please visit this
https://www.rootsanalysis.com/....reports/250/request-

Key Market Insights

Presently, more than 275 players offer contract manufacturing services for biologics
This segment of the industry is dominated by the presence of mid-sized players (51-200 employees) and start-ups / small players (2-50 employees), which collectively represent more than 80% of the total contract manufacturers. In addition, it is important to mention that about 33% of the firms were founded post 2010.

Approximately 60% of the players carry out manufacturing operations across all scales of operation
More than 60% of the service providers are engaged in manufacturing of recombinant proteins and peptides. This was followed by 49% CMOs that claim to have the required capabilities to provide antibody manufacturing services. It is worth mentioning that a number of biologic manufacturers in this domain have the required capabilities to provide manufacturing services for niche and upcoming classes of biologics, such as ADCs, cell therapies, gene therapies and plasmid DNA.

450+ manufacturing facilities dedicated to biologic-based therapies have been established globally
North America has emerged as a key manufacturing hub for biotherapeutics, featuring the presence of nearly 33% of the total manufacturing facilities. This is followed by facilities located in Europe and Asia-Pacific. Prominent manufacturing hubs within Europe include (in decreasing order of number of facilities) Germany, the UK, France, Italy and Spain.

800 partnerships were established in this domain, during the period 2015-2022
Partnership activity of biologic contract manufacturers has increased at a CAGR of 42%, during the given period. Manufacturing agreements emerged as the most popular type of partnership model adopted by industry stakeholders (37%), followed by product development and manufacturing agreements (19%). Further, over 80% of the expansion projects undertaken by industry stakeholders were initiated since 2020.

Currently, 54% of the overall, installed biopharmaceutical contract manufacturing capacity is for mammalian expression systems
The maximum (49%) capacity is installed with players companies based in Asia-Pacific. It is worth mentioning that the aforementioned region has a higher number of players engaged in biopharmaceutical contract manufacturing, which have further established multiple production facilities. This is followed by the capacity available with players having headquarters in North America (25%) and Europe (24%).

For additional details, please visit
https://www.rootsanalysis.com/....reports/view_documen

You may also be interested in the following titles:
1. Peptide Therapeutics: Contract API Manufacturing Market: Industry Trends and Global Forecasts, 2022-2035
2. Biopharmaceutical Excipient Manufacturing Market: Industry Trends and Global Forecasts, 2022-2035




Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com

SINGLE-USE SENSORS FOR BIOPROCESSING MARKET– CURRENT AND FUTURE MARKET POTENTIAL

The sensors can be classified based on the type of variables measured, which include chemical variables (pH, dissolved oxygen or substrate or product concentration), physical variables (temperature, pressure, or viscosity), and biological variables (biomass concentration/morphology or biomass productivity).

Sensors are used to detect events or changes in environment parameters during a bioprocess control. These sensors can also be classified on the basis of different principles used for measuring the variables, such as electrochemical sensors, optical chemosensor systems (known as optodes), optical spectroscopic sensors, and calorimetric sensors.
Further, sensors can be classified on the basis of their placement and integration within the bioreactor. sensors and controllers can be submerged in a liquid phase inside the bioreactor, submerged in a gas phase inside the bioreactor, in the exhaust gas stream, or placed with no physical connection to the bioreactor. Based on the abovementioned classification the sensors can be broadly categorized as follows:
 At-line Sensors: These types of sensors provide data obtained by procedures performed after a short delay in the sampling and analysis. In case of filtration for high-performance liquid chromatography analysis and derivatization for gas chromatography, analytes are accessible after pre-treatment only.
 In-line sensors (known as in situ sensors): These sensor types are in direct contact with the process, either with the liquid or gas phase. These help in providing data of the bioprocess in an online format.
Single-use sensors offer a number of benefits, such as ease of use, and convenience components, while providing the accuracy and robustness of traditional measurement techniques. Further improvements in analytical equipment, sensors and probes may facilitate process quantification and process analytical technology (PAT). Therefore, as bioprocessing processes becomes increasingly monitored by improved and novel detection methods (chemical, physical, and microbiological) and assays including single-use sensors, the output obtained can be further used for mathematical modeling and risk analysis.
The key advantages associated with SUT include reduced risk of cross-contamination, lower capital expenditure, and flexibility. Single-use bioprocessing systems are known to significantly reduce operation and manufacturing costs along with maintaining the overall quality of the product. The major advantages offered by single-use technologies are listed below:
 Cost Reduction
 Increased Productivity
 Easy Disposal
 Less Energy and Water Demand
 Time Saving
 Reduced Risk of Cross-Contamination

For additional details, please visit https://www.rootsanalysis.com/....reports/single-use-s

You may also be interested in the following titles:
1. Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (4th Edition), 2021-2030
2. Global T-Cell (CAR-T, TCR, and TIL) Therapies Market (5th Edition), 2020-2030
3. Oncolytic Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/compa....ny/roots-analysis/my
Twitter - https://twitter.com/RootsAnalysis
Medium - https://medium.com/@RootsAnalysis
Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
Quora - https://rootsanalysisinsights.quora.com/

The automatic sampling systems market is anticipated to grow at a CAGR of over 15% by 2035, claims Roots Analysis

Given the advanced features and cost saving potential, automatic sampling systems have been widely adopted by various stakeholders in biopharmaceutical industry, to monitor data in real-time and reduce deviations associated with manual sampling.

London

Roots Analysis has announced the addition of “Automatic Sampling in Biopharmaceuticals Applications and the Measurement of CQA, 2022-2035” report to its list of offerings.

The automatic sampling systems have diverse applications, including bioprocess / analyte monitoring, data management and advanced process control / feedback control, in biotechnology and pharmaceutical industries. As a result, several bioprocess equipment developers have been engaged in the development of user-friendly, controlled, and automated systems to increase the productivity and flexibility of the bioprocess. During each stage of biopharmaceutical manufacturing process, it is essential to ensure that the bioprocess variables and parameters are under control. Sampling is considered to be an important step in the bioprocess. However, there are several challenges associated with conventional, manual aseptic sampling technique, such as high risk of contamination of the sample, high labor costs, operator-to-operator deviations during sampling and sample preparation, lower sample frequency rates and no real-time availability of data. This has created a demand for systems that allow aseptic sampling and handling of samples, reduce errors, and increase reproducibility.

Key Market Insights

Currently, more than 55 automatic sampling systems are available in the market
Majority (71%) of the automatic sampling systems are capable of on-line monitoring, followed by off-line (22%) and at-line monitoring (7%). It is worth noting that around 25% of the automatic sampling systems offer multiplexer module for withdrawing the sterile samples, followed by systems containing routing module (23%) that can transfer the sample to various analyzers.

Around 45 companies are presently engaged in the manufacturing of automatic sampling systems, globally
The automatic sampling industry is dominated by the presence of mid-sized players (51-200 employees), representing more than 40% of the total automatic sampling system manufacturers. Further, about 15% firms were established post-2010. In addition, majority (54%) of the players engaged in this domain are based in Europe, followed by North America (32%).

Close to 20 automatic sample collection / preparation systems are presently available
Majority of the automatic sample collection / preparation systems (84%) are stand-alone systems. This is followed by integrated systems which capture 16% share in this domain. Further, most of these systems (nearly 40%) are being used in the pharmaceutical industry, followed by the biotechnology industry (35%).

Over 400 patents related to automatic sampling in biopharmaceutical industry have been filed / granted, since 2016
Owing to the increase in research and development efforts led by several industry and non-industry players engaged in this domain, close to 50% of patent applications have been filed post-2016. It is worth noting that 56% patents related to automatic sampling systems were filed / granted in the US alone.

Partnership activity in this field has increased at a CAGR of nearly 30%, between 2017 and 2021
Around 45% of the deals were inked in 2020 and 2021. Majority of the instances captured in the report (~40%) were product distribution agreements. Further, most of the agreements were inked with players based in North America (nearly 70%).

Over 25 global events related to automatic sampling systems were organized in the past couple of years
Majority (~80%) of the events related to automatic sampling systems, were organized virtually in order to comply with the guidelines in the ongoing COVID-19 pandemic. It is worth highlighting that the agendas of the events organized post-2020 include discussions on the potential, advancements and challenges associated with these systems in various bioprocessing operations.

North America is anticipated to capture over 50% of the global market share for automatic sampling systems, by 2035
The market will be primarily driven by sales of automatic sampling systems capable of on-line monitoring (59%). Further, systems which are used in upstream bioprocessing method are expected to occupy a larger share (60%) of the overall market (in terms of sales-based revenues), by 2035.

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/....reports/automatic-sa

Key Questions Answered
 Who are the key players engaged in the development of automatic sampling systems?
 What is the relative competitiveness of different automatic sampling system manufacturers?
 Who are the leading manufacturers involved in the automatic sample collection / preparation systems market?
 How has the intellectual property landscape of automatic sampling systems evolved over the years?
 What are the key agenda items being discussed in the various global events / conferences related to automatic sampling systems?
 Which partnership models are most commonly adopted by stakeholders engaged in the automatic sampling industry?
 How is the current and future market opportunity, likely to be distributed across key market segments?

The financial opportunity within the automatic sampling systems market has been analyzed across the following segments:
 Type of Monitoring Method
 On-line
 Off-line
 At-line

 Bioprocessing Method
 Upstream
 Downstream

 Working Volume
 Less than 10 mL
 10-50 mL
 51-100 mL
 More than 100 mL

 Scalability
 Lab
 Pilot
 Commercial

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific and Rest of the World

The research also includes detailed profiles of the key players (listed below) engaged in the manufacturing of automatic sampling systems; each profile features an overview of the company, its financial information (if available), details on product portfolio, recent developments and an informed future outlook.
 Agilent Technologies
 Cytiva
 Mettler Toledo
 Pall Corporation
 Shimadzu
 Xylem

For additional details, please visit
https://www.rootsanalysis.com/....reports/automatic-sa
or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/compa....ny/roots-analysis/my
Twitter - https://twitter.com/RootsAnalysis
Medium - https://medium.com/@RootsAnalysis
Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
Quora - https://rootsanalysisinsights.quora.com/